Article Information
- Received February 10, 2011
- Revision received September 9, 2011
- Accepted September 19, 2011
- First published November 2, 2011.
- Version of record published November 2, 2011.
Author Information
Author contributions
Author contributions: N.S.D. and D.M.R. designed research; N.S.D. and D.M.R. performed research; N.S.D. and D.M.R. analyzed data; N.S.D. and D.M.R. wrote the paper.
Disclosures
- Received February 10, 2011.
- Revision received September 9, 2011.
- Accepted September 19, 2011.
D.M.R. is supported by R01 NS064030-01A1 and by a National Alliance for Research on Schizophrenia and Depression (NARSAD) Young Investigator Award. N.S.D. is supported by T32 HL07953. We are grateful to Jean-Louis Bessereau for the gift of anti-UNC-49 antibodies and for detailed staining protocols. We thank Erik Jorgensen, Cheryl Van Buskirk, and the C. elegans Genetics Center (which is funded by the NIH National Center for Research Resources) for providing strains and Jazz Pharmaceutical for providing sodium oxybate. We thank Annesia Lamb, Robert Driver, and Kun He Lee for technical assistance. For comments on this manuscript, we thank Matt Nelson, Nick Trojanowski, Sarah McLoughlin, and Todd Lamitina.
The authors declare no competing financial interests.
- Correspondence should be addressed to David M. Raizen Department of Neurology, Perelman School of Medicine at the University of Pennsylvania, 464 Stemmler, 415 Curie Boulevard, Philadelphia, PA 19014. raizen{at}mail.med.upenn.edu
Online Impact